REC Ref No.	IRAS No.	Name of Trial	Date First Participant	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By	Date Site Confirmed	Non- Confirmation	Date Site Ready To Start	Reasons for delay correspond
			Recruited				Sponsor		Status		to:
21/NE/0101	1003829	Phase 1/2a, Single Dose Study Investigating NTLA-5001 in Subjects with Acute Myeloid Leukemia		31/08/2021	21/09/2021						
21/FT/0125	302263	A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors		30/06/2021	13/09/2021						
20/NW/0381	1003380	A Randomised, Open-Label, Parallel-Group, Pre surgical Study to Investigate the Biological Effects of AZD9833 in Women with ER-positive, HER2-negative Primary Breast Cancer		16/07/2021	09/09/2021						
21/EE/0158	298166	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)			24/08/2021	11/08/2021					
21/EE/0157	298165	A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)			29/09/2021	11/08/2021					
21/FT/0069	290279	A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy		24/08/2021	24/08/2021						
21/FT/0086	300118	A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia		05/08/2021	05/08/2021	27/07/2021					
21/LO/0412	288722	Statins in Organ Donor Management An evaluation of the benefits of a single dose of Simvastatin given to potential organ donors declared dead by neurological criteria on outcomes in organ recipients		23/07/2021	31/08/2021	28/06/2021	30/09/2021	30/09/2021		12/10/2021	
21/YH/0049		A PHASE III, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY			10/09/2021						
21/NI/0107	1003737	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy		03/03/2021	03/08/2021						

		T						_	
21/SC/0261	300456	Post-approval follow-up for the COV001 and 002 trials, to determine the longterm safety and character of immunological response to the ChAdOx1 nCoV-19 coronavirus vaccine	05/08/2021	31/08/2021	20/08/2021	11/10/2021	14/10/2021		
21/WA/0165	289626	An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)	29/07/2021	09/08/2021	02/07/2021				
21/LO/0325	296099	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients with Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract	17/09/2020	04/08/2021					
21/SC/0187	1003729	A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER (INTRINSIC)	24/06/2021	24/06/2021	13/07/2021				Sponsor
21/LO/0150	280335	A Randomised phase II trial of Enhancement of efficacy of Atezolizumab by Radiotherapy in Metastatic urothelial carcinoma		24/08/2021	09/03/2021				
20/NE/0198	278450	A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss	05/08/2021	25/08/2021					
21/FT/0102	300762	A Phase 1, Open-label, Multi-part Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and CNS Signal of the Positron Emission Tomography Ligand 11C-BMS-986196 in Healthy Participants after Intravenous Administration and to Evaluate the Safety, Tolerability, Kinetics, and CNS Signal Repeatability of 11C-BMS-986196 after Repeat Intravenous Administration in Participants with Multiple Sclerosis	08/08/2021	27/08/2021					
21/WM/0127	287139	Seal-G and Seal-G MIST study for reinforcement and protection of colonic anastomoses in Subjects undergoing colonic resection	20/07/2021	12/08/2021	05/07/2021				
21/NW/0221	1003973	A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer	30/06/2021	03/08/2021					
21/NW/0206	291351	A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis	21/07/2021	16/08/2021					
	297323	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER	23/04/2021	22/07/2021					Sponsor
20/YH/0061	265127	A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis.	10/12/2021	14/07/2021	07/04/2020				NHS Provider

21/HRA/3072	302634	A Phase III, Multicentre, Randomised Trial Comparing SARS-CoV-2 Re-Boost Vaccine Strategies in Immunocompromised	14/07/2021	27/07/2021		05/08/2021	05/08/2021	05/08/	2021
21/WA/0195	294538	Patients A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)		01/09/2021	17/08/2021				
19/EE/0228	260350	Sugar or Salt (SOS) Trial: Hyperosmolar therapy in traumatic brain injury	06/07/2021	13/08/2021	18/12/2019				
20/LO/1285	285539	Phase 3 study evaluating the safety and efficacy of an investigational drug (Debio 1143) in combination with standard platinum-based concomitant chemoradiotherapy for patients who are treatment naive, inoperable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN)		02/09/2021					
19/NW/0158	259931	A multi-centre prospective randomised superiority trial of operative fixation versus non-operative treatment for medial epicondyle fractures of the humerus in children.	06/07/2021	06/07/2021	25/03/2019				Sponsor
21/NW/0129	297718	A Phase 2 Study to Assess the Efficacy and Safety of AX-8 in Patients with Chronic Cough	30/06/2021	02/07/2021		10/06/2021	20/08/2021	20/08/	2021 Sponsor
21/LO/0467	300194	A dose confirmation study of FLT180a (adeno-associated viral vector containing the Padua variant of a codon-optimized human Factor IX gene) in adult subjects with hemophilia B - FLT180a-06	29/06/2021	23/08/2021	19/08/2021				
21/LO/0396	290966	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease	22/06/2021	09/07/2021					Sponsor
21/NE/0114	301115	A Phase II, randomised, single-blind, platform trial to assess safety, reactogenicity and immunogenicity of COVID-19 vaccines in pregnant women in the United Kingdom	16/06/2021	06/08/2021		07/09/2021	07/09/2021	23/09/	2021
21/NW/0186	1003821	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)		14/06/2021	26/07/2021				Sponsor
20/LO/1002	269769	Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children	18/06/2021	22/07/2021					Sponsor
21/LO/0216	292031	Duroplasty for Injured cervical Spinal Cord with Uncontrolled Swelling	15/06/2021	16/06/2021	24/05/2021				Sponsor
21/LO/0297	296568	Efficacy and safety investigation of NNC0194-0499 co- administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial	08/07/2021	02/09/2021		01/10/2021	01/10/2021	06/10/	2021

21/NW/0039	294490	A Modu lar, Ph ase II, Open-Label, Multicentre Study to		01/09/2021					
		Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Solid Tumours that have Progressed following Therapy with Current Standard of Care							
21/EE/0084	289545	PRotocolised Evaluation of permiSSive blood pressure		04/06/2021		04/06/2021			Sponsor
		targets versus Usual caRE. Evaluating the clinical and cost effectiveness of using a permissive blood pressure target to guide titration of vasoactive drugs in critically ill children with hypotension.							·
21/LO/0558	299581	Addition of probenecid to penicillin-V therapy: an open label, cross-over study in healthy volunteers	28/06/2021	16/09/2021	16/09/2021				
19/SC/0344	263202	Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE) is referred to as the GSR DEFINE study.	02/04/2021	21/07/2021	07/07/2021	30/09/2021	07/10/2021		Sponsor
21/FT/0062	297859	A Phase 1b/2a Study of VB119 in Adult Subjects with Primary Membranous Nephropathy	16/06/2021	27/07/2021					
21/HRA/3145	294856	URAISE:Ultrasound Regional Anaesthesia Interpretation Skill Evaluation	01/06/2021	02/09/2021	02/09/2021	02/09/2021	30/09/2021	30/09/2021	
20/EE/0293	276366	Vitrectomy and subretinal TPA for submacular haemorrhage secondary to wet AMD (TIGER)	28/05/2021	10/06/2021	19/02/2021	14/09/2021	14/09/2021		Sponsor
20/NW/0438	287737	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)-PRN1008-018	27/04/2021	10/08/2021					
20/WM/0219	251596	Multi-Centre, open-label, randomised, prospective trial to assess efficacy and safety of the CADDIE artificial intelligence system for improving endoscopic quality	12/05/2021	22/06/2021	09/10/2020	13/10/2021	18/10/2021	18/10/2021	Sponsor
	281231	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS	14/05/2020		04/01/2021	29/07/2021	27/08/2021	13/10/2021	
18/WA/0199	108978	AZTEC: Azithromycin Therapy for Chronic Lung Disease of Prematurity A randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease		14/05/2021			08/10/2021		Sponsor
16/EM/0186	173279	Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo) Radiotherapy versus Total mesorectal excision for early REctal Cancer	28/04/2021	24/06/2021					NHS Provider
20YH/0232	280105	ATNEC – A randomised trial investigating the requirement for axillary treatment, after chemotherapy, for patients with early stage breast cancer	17/05/2021	17/05/2021	22/10/2020	14/09/2021	14/09/2021		Both
		early stage breast cancer							

20/NW/0340	1003335	A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-	10/05/2021	15/06/2021	18/09/2020	20/08/2021	24/08/2021			NHS Provider
		BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS								
20/SC/0326	286972	A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma	23/02/2021	12/05/2021		08/10/2021	12/10/2021			Sponsor
21/NW/0055	1003596	A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension	23/03/2021	30/07/2021	07/05/2021					
20/SC/0403	288652	PROphylaxis for paTiEnts at risk of COVID-19 infecTion	05/05/2021	05/05/2021		06/07/2021	05/07/2021			Sponsor
21/YH/0191	298744	Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a phase III, randomized, controlled, double blind, two-armed clinical study.	13/08/2021	03/09/2021						
21/WS/0080	1003802	FORWARDS; Evaluating the safety of acute baclofen in methadone-maintained individuals with opiate dependence	16/06/2021	13/08/2021						
21/FT/0050	294543	A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer's disease (EVOKE plus)	29/04/2021	01/06/2021	20/05/2021	11/10/2021	13/10/2021			Sponsor
21/FT/0049	294544	A randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer's disease (EVOKE)	12/03/2021	24/05/2021	20/05/2021	11/10/2021	13/10/2021			Sponsor
18/NW/0432	239796	Safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer	03/03/2021	16/07/2021	03/09/2018	07/09/2021	17/09/2021		20/09/2021	Sponsor
21/EM/0102	294776	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)	14/05/2021	23/07/2021			11/10/2021			Neither
19/SW/0209	257547	Proper Understanding of Recurrent Stress Urinary Incontinence Treatment in Women: A Randomised Controlled Trial of Endoscopic and Surgical Treatment	19/04/2021	21/04/2021	19/12/2019		Site	declined to partic	ipate	
20/LO/0027	263262	CONCEPT STUDY: COmparing the effectiveness of phacoemulsificatioN + ECP lasEr and Phacoemulsification alone for the treatment of primary open angle glaucoma in patients with cataract – a randomised controlled Trial	16/04/2021	12/05/2021	24/02/2020	28/06/2021	29/06/2021		15/07/2021	Sponsor
21/WS/0036		A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) – The COASTAL Study		21/04/2021						Sponsor
21/PR/0767	297548	Autonomous telephone follow-up after cataract surgery	18/06/2021	18/06/2021	01/07/2021	30/09/2021	30/09/2021		30/09/2021	Sponsor
21/NI/0032	1003609	A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB	08/03/2021	20/04/2021	05/05/2021	04/08/2021	09/08/2021		15/09/2021	Neither

21/SC/0121	294861	HElping Alleviate the Longer-term consequences of COVID-19(HEAL-COVID): a national platform trial	29/09/2021	12/04/2021	30/04/2021		05/07/2021	05/07/2021	08/07/2021	Sponsor
		To(TE/TE 00 VID). a Hadonal placeon tital								
20/WA/0121	276396	British Heart Foundation Randomised Clinical Trial of Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation (BHF PROTECT-TAVI)		18/02/2021	16/08/2021	28/05/2020	21/09/2021	13/10/2021		
19/WA/0019		Reduction Of Surgical Site Infection using several Novel Interventions		31/03/2021	07/04/2021	04/07/2019				Sponsor
20/HRA/6152	292509	The LAVA (Lateral flow Antigen Validation and Applicability) 2 Study for COVID-19		30/03/2021	12/08/2021		14/09/2021	14/09/2021		
21/LO/0659	294514	The SABRE Trial: A single arm prospective study measuring immune correlates of protection against SARS-CoV-2 virus infection amongst high-risk special populations after subcutaneous dosing of two SARS-CoV-2 neutralising antibodies (C135-LS and C144-LS)		18/08/2021	18/08/2021					
21/NW/0149	296372	Cryoanalgesia for rib fracture pain		31/03/2021	23/07/2021	23/07/2021	16/09/2021	16/09/2021	16/09/2021	NHS Provider
21/WM/0013	283141	Hysteroscopic Excision of Leiomyoma and Polyp in Infertility		04/03/2021	25/05/2021			Site	declined to participate	
21/EE/0055	1003560	A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE		18/03/2021	21/07/2021	06/05/2021		27/07/2021	17/09/2021	Sponsor
21/EE/0039	290104	A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY		09/02/2021	28/07/2021		17/09/2021			
21/LO/0177	290367	A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients		13/01/2021	08/03/2021		30/09/2021	07/10/2021	18/10/2021	Sponsor
21/SC/0084	293797	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19		05/03/2021	05/03/2021		19/04/2021	06/05/2021	27/05/2021	Neither
20/LO/1061	276250	Attentional Therapy for the TrEatment of Neglect Disorder (ATTEND)		05/03/2021	07/06/2021		13/07/2021	13/07/2021	15/09/2021	Sponsor
	277059	The HUmeral SHaft fracture trial: A multi-centre prospective randomised superiority trial of surgical versus non-surgical interventions for humeral shaft fractures in patients aged 18 years or older		16/02/2021	16/02/2021	02/06/2020	07/06/2021	17/06/2021	29/07/2021	Both
21/HRA/0489	294480	OCTAVE: Observational Cohorts Trial - T-cells Antibodies and Vaccine Efficacy in SARS-CoV-2	17/03/2021	17/02/2021	05/03/2021		09/03/2021	09/03/2021	10/03/2021	

20/ES/0122	1003500	Efficacy and Safety Assessment of T4030 Eye Drops versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patient	09/02/2	021 09/02/2021		24/09/2021	28/09/2021			Sponsor
21/FT/0040	291127	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ROZANOLIXIZUMAB IN ADULT STUDY PARTICIPANTS WITH LEUCINE-RICH GLIOMA INACTIVATED 1 AUTOIMMUNE ENCEPHALITIS	24/03/2							
21/LO/0261	291828	Multi-centre, pilot study evaluating the feasibility, acceptability and short-term outcomes of a tailored, virtual, home-based, multicomponent prehabilitation programme in patients undergoing abdominal aortic aneurysms (AAA) repair		18/05/2021	10/05/2021	29/07/2021	03/08/2021		04/08/2021	Sponsor
21/WS/0079	291666	Improving mental health following early pregnancy loss using a brief cognitive task: a randomised controlled study	23/04/2	26/07/2021	27/07/2021					Sponsor
20/WS/0171	281799	Physiologic Pacing Registry	28/01/2	021 08/02/2021			Site	declined to partic	ipate	
19/WS/0107	256189	A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications	01/02/2	02/03/2021	05/11/2019	27/05/2021	03/08/2021		12/08/2021	Neither
21/WA/0030	293576	A randomised controlled trial of scanning eye training as a rehabilitation choice for hemianopia after stroke (SEARCH)	29/01/2	021 01/02/2021	12/03/2021	28/05/2021	01/06/2021		01/06/2021	NHS Provider
21/SS/0007	292045	A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)	13/10/2	02/02/2021		08/06/2021	01/07/2021		16/07/2021	Neither
21/EE/0017	282284	ELEVATE: Temozolomide + nivolumab in MGMT deficient oesophagogastric cancer	25/01/2	021 25/01/2021			Site	declined to partic	ipate	
21/FT/0058	293068	A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors	29/04/2	021 18/05/2021	17/05/2021	24/09/2021	28/09/2021			NHS Provider
20/EE/0254	283893	AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER		20/01/2021	20/01/2021	10/06/2021	24/06/2021		18/06/2021	Neither
	268864	MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study	03/03/2							
20/SC/0377	287169	Recombinant Factor VIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial	03/03/2	021 03/03/2021			Site	declined to partic	ipate	

0.4 /5 11.4 / 0.0 0.0		10 11 11 11 11 11 11 11 11 11 11 11 11 1		1 4 2 / 2 4 / 2 2 2 4	4=/00/0004						
21/NW/0080	292573	Suitability of an aerosol removing device (iZephyr hood) for		19/01/2021	17/09/2021						
		COVID-19 patients using non-invasive ventilation or high flow									
		oxygen therapy									
20/HRA/6338	293815	A randomised, multicentre post-exposure prophylaxis (PEP)		13/01/2021	19/02/2021			15/03/2021			Neither
		clinical trial evaluating RESP301, an inhaled therapy for									
		treatment of lung infections, for prevention of onward									
		transmission of viral infections including SARS-CoV-2 to									
		household members.									
20/SC/0372	283157	Intramuscular tranexamic acid for the treatment of		05/01/2020	26/05/2021	17/12/2020		Site	declined to partic	ipate	
		symptomatic mild traumatic brain injury in older adults: a							·	•	
		randomized, double-blind, placebo-controlled trial.									
20/EE/0252	276415	Pharmacological management of seizures post traumatic	26/05/2021	11/12/2020	18/12/2020	20/01/2021		07/04/2021		26/04/2021	Neither
20,22,0202		brain injury	20,00,202	1 17 12/2020	10/12/2020	20/01/2021		0170172021		20/01/2021	11011101
		Julian injury									
15/SC/0293	170015	Designature of Design Dusin Chineseletion with the VEDCICETM		20/44/2020	40/04/0004	02/00/2045					Cnanaar
15/50/0293	178915	Registry of Deep Brain Stimulation with the VERCISE™		20/11/2020	12/04/2021	03/06/2015					Sponsor
		System for treatment of Dystonia: Vercise DBS Dystonia									
00/00/0450	004040	Registry		4.4/4.0/0.000	00/00/0004						0
20/SC/0450	291949	A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm,		14/12/2020	03/03/2021						Sponsor
		216 Week Study to Evaluate Efficacy and Safety of									
		Treatment With BAN2401 in Subjects With Preclinical									
		Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in									
		Subjects With Early Preclinical Alzheimer's Disease and									
		Intermediate Amyloid (A3 Trial)									
20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled		24/12/2020	02/01/2021		16/02/2021	16/02/2021		26/02/2021	Sponsor
		Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-									
		5734TM) Treatment of COVID-19 in an Outpatient Setting									
19/EE/0377	266504	Trial of Ondansetron as a Parkinson's HAllucinations		07/12/2020	01/02/2021		08/04/2021	08/04/2021		08/06/2021	Sponsor
		Treatment									
20/SC/0111	276734	A Multicenter, Open-Label, Randomized Phase III Study to	23/04/2021	27/11/2020	07/12/2020		01/04/2021	12/04/2021		14/04/2021	Sponsor
		Evaluate the Efficacy and Safety of the Combination of									
		Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-									
		Vd) Compared with the Combination of Daratumumab,									
		Bortezomib and Dexamethasone (D-Vd) in Participants with									
		Relapsed/Refractory Multiple Myeloma									
20/LO/1278	288502	A multicenter, Phase 2a, open-label, non-randomized study		26/11/2020	07/12/2020	26/01/2021	28/01/2021	02/02/2021			Neither
		evaluating the efficacy, safety, and tolerability of BIVV020 in									
		adults with persistent/chronic immune thrombocytopenia									
		(ITP)-PDY16894									
20/NW/0300	285728	A Phase 3, randomized, double-blind, efficacy and safety		23/11/2020	01/09/2021	15/09/2020	30/09/2021	30/09/2021			
		study comparing SAR442168 to placebo in participants with									
		nonrelapsing secondary progressive multiplesclerosis									
		(HERCULES)									
20/SW/0186	290807	INTERVENTION 1 PROTOCOL (Xarelto): A randomized,		04/12/2020	08/12/2020		11/01/2021	12/01/2021			Neither
20,000,0100	200007	controlled, Phase 2b study to evaluate safety and efficacy of		34/12/2020	00/12/2020		11/01/2021	12/01/2021			14010101
		rivaroxaban (Xarelto®) for high risk people with mild COVID-									
		19									
		10									

21/WA/0103	291833	INTERvention with Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation (INTERCEPTavi): 'Carbon-Dioxide Flushing versus Saline Flushing of Transcatheter Aortic Valves: A Single-centre Randomised Controlled Trial'	29/07/2021	22/02/2021	27/04/2021	20/04/2021	03/06/2021	08/06/2021	08/06/2021	Sponsor
20/LO/1291	292074	The effect of semaglutide in subjects with non-cirrhotic non- alcoholic steatohepatitis		03/12/2020	02/03/2021		17/03/2021	13/04/2021	16/04/2021	Neither
21/LO/0203	288725	ORBITA-COSMIC: Coronary sinus reducer Objective impact on Symptoms, MRI Ischaemia and microvascular Resistance		04/02/2021	29/03/2021	27/03/2021	21/05/2021	21/05/2021	21/05/2021	
21/LO/0520	294670	Lead EvaluAtion for Defibrillation and Reliability(LEADR)		19/11/2020	03/08/2021					
20/LO/1129	1003422	A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance.		17/11/2020	29/06/2021	21/12/2020	30/07/2021	06/08/2021	12/08/2021	Sponsor
18/LO/2070	246179	TAPS2: Transfusions Antenatally in Pregnant women with SCD		16/10/2020	14/07/2021	23/10/2019	06/10/2021	06/10/2021		Sponsor
20/WM/0297	288227	A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)		09/11/2020	10/08/2021					
20/NI/0070	1003313	Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma		07/10/2020	07/06/2021	07/07/2020				NHS Provider
20/WM/0195	268363	A multi-centre phase II trial of GVHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide		27/11/2020	30/11/2020		05/03/2021	08/03/2021	17/03/2021	Sponsor
20/NW/0487	289272	Do the results of intra-operative margin assessment correlate with the output of conventional histology for patient undergoing breast conservation surgery?	04/06/2021	15/12/2020	11/01/2021	18/01/2021	14/05/2021	27/05/2021	01/06/2021	NHS Provider
20/SC/0018	258872	A randomised controlled trial assessing if microsurgical nerve repair offers clinical benefit and cost effectiveness (in terms of patient–reported hand function, sensory recovery and adverse events) over exploration and washout without microsurgical nerve repair in adult patients with recent traumatic digital nerve injury.	23/07/2021	07/10/2020	25/11/2020	13/02/2020	09/06/2021	21/06/2021	23/07/2021	Neither

04/01/1/0040	14000500	A Discussion Developed to Developed to Controlled	ı	45/00/0004	07/00/0004			I	ı		1
21/SW/0016	1003529	A Phase 3, Randomized, Double-Blind, Placebo-Controlled		15/02/2021	27/09/2021						
		Study to Compare the Efficacy and Safety of Sotatercept									
		Versus Placebo When Added to Background Pulmonary									
		Arterial Hypertension (PAH) Therapy for the Treatment of									
04/1 0/0000	000747	PAH.		40/40/0000	45/00/0004	40/00/0004					
21/LO/0366	290747	Intra-operative ultrasound guided laparoscopic ovarian		19/10/2020	15/08/2021	13/08/2021					
		cystectomy (UGLOC) in the management of benign ovarian									
		cysts: Randomised Controlled Trial									_
20/LO/1056	277635	Venetoclax or Intensive Chemotherapy for Treatment Of		13/10/2020	12/11/2020		01/04/2021	06/04/2021		01/06/2021	Sponsor
		Favourable Risk Acute Myeloid Leukaemia: A Molecularly									
		Guided Phase 2 Study									
20/NW/0463	1003437	Phase 2 Study of MK-6482 in Participants With Advanced			17/05/2021		19/04/2021	02/06/2021		16/06/2021	Neither
		Renal Cell Carcinoma									
21/LO/0051	285417	Diagnosis of Heart Failure in the Post-COVID-19 Clinic,	15/04/2021	19/10/2020	29/03/2021	05/02/2021	13/04/2021	15/04/2021		15/04/2021	
		Primary Care and Hospital Setting Using a Digital									
		Stethoscope with AI ECG									
21/NW/0175	280580	Omnipolar Voltage-Based Substrate Characterisation of the	06/09/2021	19/10/2020	04/08/2021	20/07/2021	06/07/2021	13/08/2021		13/08/2021	
		Left Atrium in Persistent Atrial Fibrillation.									
20/LO/0840	264482	Functional and Ultrasound guided Resection of	15/06/2021	16/10/2020	30/04/2021	05/10/2020	12/05/2021	12/05/2021		24/05/2021	
		Glioblastoma. A two stage trial. Stage 1 – Non-randomised									
		collaborative learning and evaluation phase of participating									
		centres (IDEAL Stage 2b study), followed by Stage 2 – A									
		Multicentre Phase III trial with 2 mechanistic substudies.									
20/LO/0196	271343	PreOperative Endocrine Therapy for Individualised Care with		05/10/2020	29/04/2021	08/07/2020	29/04/2021	08/07/2021		19/07/2021	Neither
		Abemaciclib									
20/LO/1157	281627	An open-label, randomized, controlled phase 3 study of		09/10/2020	15/07/2021	17/12/2020	17/09/2021	12/10/2021			Neither
		enfortumab vedotin in combination with pembrolizumab with									
		or without chemotherapy, versus chemotherapy alone in									
		previously untreated locally advanced or metastatic urothelial									
		cancer									
20/LO/1106	286152	Phase 1b, Multicentre, Multiple Ascending Dose, Safety,		23/09/2020	11/01/2021		05/02/2021	09/04/2021		26/04/2021	Neither
		Pharmacokinetic, and Pharmacodynamic Study of									
		Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-									
		grade Serous Ovarian Cancer (HGSOC) Patients									
18/NW/0644	248582	A prospective open label, pharmacokinetic study of an oral		24/09/2020	05/11/2020			Site	declined to partici	pate	
		hydroxyurea solution in children with sickle cell anemia									
20/SC/0117	269627	A two-year, phase III randomized, double-blind, parallel-		27/10/2020	17/11/2020						Neither
		group, placebo-controlled trial to evaluate the safety,									
		efficacy, and tolerability of 300 mg s.c. Secukinumab versus									
		placebo, in combination with SoC therapy, in patients with									
		active Lupus Nephritis (SELUNE)									
19/EE/0384	275752	VenaSeal Spectrum: Global, Post-Market, Prospective, Multi-	20/08/2021	01/09/2020	11/02/2021	06/04/2020	30/06/2021	19/07/2021		11/08/2021	Neither
		Center, Randomized Controlled Trial of the VenaSeal™									
		Closure System vs. Surgical Stripping or Endothermal									
		Ablation (ETA) for the Treatment of Early and Advanced									
		Stage Superficial Venous Disease									
21/YH/0056	283442	Prediction of Patient Drug Response Using an Ex Vivo Organ			30/06/2021	08/04/2021					Neither
		Culture (EVOC) on fresh human tumour samples from									
		Metastatic Patients									

20/LO/1115	286901	Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment naà ve Patients with Inactive Chronic Hepatitis B (CHB)		04/04/2021	02/07/2021		14/07/2021	11/08/2021	16/0	08/2021	Sponsor
20/LO/0848	272164	ALLTogether1 – A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)			02/06/2021						NHS Provider
	288552	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	26/11/2020	30/10/2020	30/10/2020		13/11/2020	16/11/2020	23/1	1/2020	
20/NE/0283	286210	An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of APL-2 in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN		28/01/2021	13/04/2021		28/04/2021	29/04/2021			Neither
20/YH/0200	281008	A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/µL)		14/09/2020	29/10/2020		29/07/2021	04/08/2021	15/0	09/2021	Sponsor
20/LO/0504	1003208	Randomised controlled trial of Gestational treatment with Ursodeoxycholic Acid compared to Metformin to Reduce effects of Diabetes mellitus		16/09/2020	29/06/2021		17/09/2021	21/09/2021			Neither
21/SC/0094	289344	A phase I study to determine safety and immunogenicity of the candidate COVID-19 vaccine ChAdOx1 nCoV-19 delivered by aerosol in healthy adult volunteers		16/03/2021	10/08/2021	22/04/2021	19/08/2021	20/08/2021			
20/SW/0117	1003162	Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration		15/09/2020	06/11/2020	01/09/2020		Site	declined to participate		
20/EM/0298	283692	Ultrasound Prediction of Delivery Mode: can the first stage prediction model be further improved?	17/05/2021		12/04/2021	18/02/2021		12/05/2021	14/0)5/2021	
20/WA/0343	273080	Transplant Renal Artery Stenosis Observation versus Stenting		26/11/2020	27/11/2020	21/12/2020	01/02/2021	04/08/2021	04/0	08/2021	Neither
21/PR/0250	281309	Neuromuscular Stimulation for Rehabilitation after general and vascular surgery - a pilot randomised clinical study	09/07/2021	11/09/2020	13/05/2021	12/05/2021	07/07/2021	07/07/2021	07/0	7/2021	
20/LO/1272	287235	A prospective randomised extended pilot study of a directed psycho-educational tool to prevent psychological sequelae following Paediatric Intensive Care admission	02/07/2021		25/03/2021	25/03/2021		13/04/2021	13/0	04/2021	Sponsor
20/LO/0009	263698	Observational cohort with embedded Randomised Controlled trials to study pregnancy-Associated progression of Renal Disease – A Feasibility Study of Dietary Nitrate (BEETroot juice) to protect kidney function in pregnant women with Chronic Kidney Disease		24/08/2020	05/01/2021		09/02/2021	09/02/2021	19/0)4/2021	Neither
17/NW/0078	220323	Product Surveillance Registry - NeuroVascular			16/06/2021						Sponsor
20/LO/1297	288071	Impact of the short chain fatty acid propionate on mesenteric adipose tissue, liver metabolism and insulin sensitivity: The PROMIS study.		08/03/2021	08/03/2021	25/01/2021	08/03/2021				Sponsor

20/WS/0133	287610	Bioimpedence and Arterial function Monitoring at Birth and in	17/12/2020		26/11/2020	24/11/2020		09/12/2020	10/12/2020	
		Infants: the BAMBI study								
18/WA/0420	246637	Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe persistent acne in women	25/05/2021	20/11/2020	13/04/2021	04/02/2019	13/05/2021	13/05/2021	21/05/2021	
20/LO/1111	286572	Prospective Evaluation to Characterize the Real-World PerFormance of the EMBOVACTM Aspiration Catheter for Neurothrombectomy: A Post-Market Clinical Follow-up Trial.	04/06/2021	21/07/2020	18/03/2021		13/04/2021	19/04/2021	24/05/2021	Sponsor
	278082	Accuracy of ECG-guided tip placement and point of care ultrasound scan (POC-US) during central line insertion in neonates – a feasibility study CLIN study	23/06/2021		04/02/2021	27/01/2021		25/05/2021	25/05/2021	Neither
20/LO/0745		Phase 1 / 2 Multicenter Study of the Safety,			09/03/2021	09/06/2020	30/03/2021	31/03/2021	07/04/2021	Neither
20/YH/0268	287353	An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection		06/07/2020	05/05/2021		29/07/2021	04/08/2021		Sponsor
20/NW/0312	284188	A Registry-based, Randomised, Double-blind, Placebo-		22/10/2020	17/08/2021	23/07/2020	02/08/2021	15/09/2021		
20/LO/1283	285961	A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cance		01/12/2020	01/12/2020					Neither
20/WM/0221	285758	LumenEye during CovID-19 (LuCID study)			05/02/2021	10/09/2020				Sponsor
20/LO/0821	281982	AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM GANTENERUMAB ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE	14/07/2021	02/05/2021	25/05/2021			28/06/2021	28/06/2021	
20/LO/0906	1003020	A Phase 2b, open-label, single-arm study of ZW25		06/04/2020	09/03/2021		08/12/2020	14/04/2021	28/04/2021	Neither
20/LO/1001	282291	A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors	16/12/2020	23/04/2020	26/10/2020	23/10/2020	19/11/2020	08/12/2020	08/12/2020	
20/LO/1070	279091	What is the impact of a modified Roux-en-Y-gastric bypass	02/03/2021	04/11/2020	16/11/2020			01/02/2021	01/02/2021	Sponsor
	278525	A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants with High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer			20/01/2021	18/06/2020	15/02/2021	25/02/2021	12/03/2021	Neither
20/NW/0310		A randomized double-blind, placebo-controlled, multicenter	23/07/2021	29/10/2019		25/09/2020	29/03/2021	05/05/2021	05/07/2021	Sponsor
	285155	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH).		11/05/2020	10/08/2021	23/11/2020	01/10/2021	08/10/2021	08/10/2021	
20/SC/0371	286893	A Phase 111, Randomised, double-blind, Placebo-controlled		04/09/2020	18/05/2021	09/12/2020	18/06/2021	24/06/2021	24/06/2021	Neither

04/1-0/0054	1000 400	A MULTIOENTRE DU OT DANIDOMICED CONTROL TRIAL		00/05/0004	00/00/0004	04/05/0004	00/40/0004	00/40/0004	20/40/0004	INILIO Des dels
21/LO/0054	283483	A MULTICENTRE PILOT RANDOMISED CONTROL TRIAL OF AN ADAPTED MOBILE REHABILITATION SYSTEM FOR SELF-DIRECTED REHABILITATION AND IMPROVED UPPER LIMB OUTCOMES IN STROKE SURVIVORS WITH UPPER LIMB WEAKNESS		26/05/2021	22/06/2021	21/05/2021	06/10/2021	06/10/2021	06/10/2021	NHS Provider
20/EM/0087	274214	An open-label, randomised, multicentre, phase III study of	10/05/2021	01/04/2020	05/03/2021	19/05/2020	28/01/2021	20/04/2021	28/04/2021	
19/LO/0288	235544	A Randomised Placebo-Controlled Trial on the effectiveness	10/03/2021		24/02/2021	09/07/2020	28/01/2021	14/05/2021	28/04/2021	Sponsor
13/23/0200	2000++	of Escitalopram and Nortriptyline for depressive symptoms in Parkinson's disease		00/00/2020	24/02/2021	00/01/2020		14/00/2021		Оролоог
20/NW/0181	238013	A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL		07/04/2020	17/11/2020		04/02/2021	12/04/2021	20/05/2021	Sponsor
19/LO/1513	264579	A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC- 90001 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS		02/04/2020	13/04/2021			Site declined to participate		
20/EE/0078	267074	A Phase 3 multicentre, double-blind, randomized, placebo-		20/03/2020	03/11/2020		01/04/2021	24/05/2021	25/05/2021	Neither
21/EM/0019	273631	Improving implantable cardioverter defibrillator arrhythmia detection: development of a novel arrhythmia detection algorithm	05/07/2021	29/12/2020	21/04/2021	30/03/2021	05/07/2021	05/07/2021	05/07/2021	Sponsor
20/SC/0116	272955	Brain connectivity and patient reported outcomes in people		02/03/2020	08/04/2021		05/05/2021	12/05/2021	08/07/2021	Sponsor
18/EE/0389	235758	Seizure PRophylaxis IN Glioma		21/02/2020	01/07/2021		24/03/2021	19/07/2021		Neither
20/NE/0014	272055	Multi-centre, randomised, open-label, blinded endpoint		20/02/2020	04/06/2021					Sponsor
19/EE/0376	270371	A Double-blind, Randomized, Placebo-controlled, Parallelgroup Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients with Spasticity Due to Multiple Sclerosis		21/05/2021	04/08/2021	25/02/2020				
20/WS/0057	277361	Erythropoietin and Darbepoetin in Neonatal Encephalopathy	12/08/2021	01/06/2020	30/03/2021	27/05/2020	27/05/2021	28/05/2021	28/05/2021	Sponsor
19/EE/0379	269900	IPX203-B16-03		01/06/2020	17/12/2020	11/10/2019	02/02/2021	02/02/2021		Neither
19/LO/1953	271361	Efficacy of BIC/F/TAF versus standard of care in the		16/09/2020	25/05/2021		25/05/2021	01/06/2021	09/06/2021	Neither
	272434	A multicenter, randomized, active-controlled, double-blind, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson's disease experiencing motor fluctuations (BouNDless).			13/01/2021	21/01/2020	19/04/2021	19/04/2021	22/09/2021	Sponsor
20/LO/0364	274161	Minimally Invasive Realtime Assessment of Continuous	11/03/2021	10/02/2020	02/11/2020	07/05/2020	15/02/2021	15/02/2021	16/02/2021	Neither
19/NW/0707	272541	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)	24/06/2021	29/11/2019	02/04/2021		14/01/2021	10/05/2021	28/05/2021	Neither
20/LO/0607	270603	Oil-based versus water-based contrast media for			03/05/2021	13/05/2021		15/10/2021		Sponsor
20/LO/0477	254910	Psychology of pregnancy of unknown location (SOUL)	02/12/2020	06/02/2020	26/10/2020	23/07/2020	02/11/2020	30/11/2020	30/11/2020	
20/LO/0068	274808	Pre-conception interventions to reduce blood pressure	02/11/2020	09/10/2020	15/10/2020			30/10/2020	02/11/2020	
18/WS/0218	252602	An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)		25/10/2019	20/11/2020	25/09/2019	26/06/2020	09/12/2020	09/12/2020	Neither
19/YH/0049	258945	A phase 1c, multicenter, randomized, observer-blinded,		19/08/2020	02/03/2021		01/06/2019	17/06/2021	05/07/2021	Sponsor

19/SW/0043		CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease): A phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease.	16/06/2021	11/09/2019	18/03/2021	26/06/2019		08/04/2021	12/05/2021	Sponsor
19/LO/1064	260639	The TIGHT-K STUDY. Prevention of dysrhythmias on the	16/06/2021	15/11/2019	19/04/2021	06/11/2019	26/04/2021	28/05/2021	04/06/2021	
19/LO/1449		Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced/Unresectable Biliary Tract Carcinoma		04/07/2019	05/10/2020	24/03/2020	10/11/2020	26/11/2020	13/01/2021	Sponsor
19/LO/1152	265415	A phase 2, open-label, single-arm, multicenter study to		02/05/2019	27/04/2021	16/08/2019	22/11/2019	06/05/2021	06/05/2021	Sponsor
20/LO/0474		Psilocybin as a Treatment for Restrictive Anorexia Nervosa: A Pilot Study	28/05/2021	09/12/2020	11/01/2021	23/06/2020	12/04/2021	12/04/2021	12/04/2021	Neither
19/LO/1669	266322	The RIO Trial: A randomised controlled trial of dual long-		14/01/2020	16/04/2021	12/12/2019	05/05/2020	10/05/2021	13/05/2021	Neither
17/NW/0581		Does Interleukin-1 Receptor Antagonist Improve Outcome following aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III trial		17/04/2019	17/05/2021					Sponsor
18/EM/0310	239782	Emergency Cervical Cerclage to Prevent Miscarriage and		11/03/2019	27/07/2021	16/01/2019		30/09/2021		
19/LO/0836		INTERvention with Cerebral Embolic Protection in TEVAR (InterCEPT): 'Carbon-Dioxide Flushing versus Saline Flushing of Thoracic Aortic Stents: A Multi-centre Randomised Controlled Trial'		22/02/2019	07/06/2021	07/06/2021	23/08/2021	15/09/2021	15/09/2021	Sponsor
20/LO/0938	1003322	A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant		07/10/2019	09/03/2021	13/11/2020	02/11/2020	18/05/2021	02/07/2021	Neither
19/SC/0144		Defining personalised outcomes in pre-school children with recurrent wheeze	13/08/2021		24/02/2021	31/05/2019		19/05/2021	25/05/2021	Neither
19/LO/0418		Singing for Health: Improving Experience of Lung Disease	22/06/2021	07/02/2019	24/11/2020	23/05/2019	07/02/2019	16/12/2020	17/12/2020	Neither
20/LO/0345		A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy (ADVANCE Capacity)		25/02/2020		19/06/2020				Neither
19/LO/0062		A study evaluating the efficacy and safety of ralinepag to		24/04/2020						Neither
20/PR/0378		Arginine Supplementation to improve Cardiovascular and Endothelial function after NSAID Treatment (ASCENT)	10/06/2021	27/04/2020	12/04/2021	12/01/2021	28/07/2020	15/04/2021	17/04/2021	
19/EE/0027	252781	PresSura Assessment of NK1 Inhibition in Traumatic Brain		14/02/2019	15/06/2021	15/10/2019				Sponsor